Amphista is identifying and advancing novel approaches in targeted protein degradation (TPD) to develop a new generation of innovative therapies with significantly improved efficacy.
The company’s proprietary Eclipsys™ Drug Development platform is rapidly expanding the therapeutic applications of this transformational modality.
Careers
Amphista offers an exciting and fast-moving working environment that fosters opportunity. Come and join our team and help us make a positive difference for patients.
Latest News
- Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium 23 May 2024
- Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders 24 January 2024